Menu
  • Publish Your Research/Review Articles in our High Quality Journal for just USD $99*+Taxes( *T&C Apply)

Review Article

A Study of Biguanides in the Care of Type II DIABETES Mellitus

Mathu Raveendran T, A Abarnadevika* and G Ariharasivakumar

Corresponding Author: A Abarnadevika, Department of Pharmacology, KMCH College of Pharmacy, Coimbatore, Tamilnadu, India

Received: February 03, 2022 ;    Revised: February 06, 2022 ;    Accepted: February 08, 2022 ;   Available Online: May 1, 2022

Citation: Mathu RT, A Abarnadevika and G Ariharasivakumar. (2022) A Study of Biguanides in the Care of Type II DIABETES Mellitus. J Pharm Sci Drug Discov, 1(1): 1-9.

Copyrights: ©2022 Mathu RT, A Abarnadevika and G Ariharasivakumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Share Your Publication :

Views & Citations

4608

Likes & Shares

0


Global Views

  • Abstract
  • Full Text
  • Images
  • Tables
  • References
  • PDF
  • Supplementary Files

Type II diabetes mellitus (T-II-DM) is now a worldwide scourge which represents a huge test to medical services frameworks. This sickness is described by higher-than-normal blood sugar levels because of a combination of insulin resistance and insufficient of insulin discharges from the β-cells of pancreatic Islets of Langerhans. Metformin and phenformin, are the major biguanides, presented in 1957 as oral glucose-reducing agents for the treatment of NIDDM (non-insulin -dependent diabetes mellitus). Phenformin was removed in numerous countries as an aftereffect of a relationship with lactic acidosis, but metformin was not like a similar hazard on the off chance that suitably recommended. Biguanides are the first line antihyperglycemic agents, mainly metformin that works chiefly by controlling hepatic glucose production and peripheral insulin affectability. Metformin is currently generally utilized as a monotherapy and in mix with a sulfonylurea metformin has been clinically applied for the greater part a century, despite the fact that the hidden pharmacological mechanisms stay tricky. This current review mainly centered on the history of biguanides, pharmacokinetics, pharmacodynamics, mechanism of action, combination therapy and adverse effects.


Keywords: Type II diabetes mellitus, Biguanides, Insulin release β-cells

Mpgyi